Prosonix: Scrap excipients for better respiratory delivery

Delivering a single drug to the lungs may be simple enough, but getting combined treatments to disperse at the same time can be a trickier challenge. Prosonix says its new platform for multi-API powders could be the way to boost effectiveness for inhaled treatments.

In a paper published in European Respiratory Disease, Prosonix touts its "smart" combination particles, which fuse active ingredients without the use of excipients. In standard mixed-powder formulations, combination treatments separate once in the body, leading to inconsistent dispersal and less effective treatment. The company's platform, however, uses ultrasonic particle engineering to combine treatments into a single, drug-only particle, in-PharmaTechnologist reports.

The result, according to Prosonix, is a more effective, efficient and tolerable treatment. The company tested its platform using a combination of Advair and Symbicort and found that the multi-component particle preserved the API ratio both in formulation and dosing, providing consistent levels of both drugs.

The development could boost the synergy of other combined respiratory therapies, too, and lead to more effective treatments, according to Prosonix's CEO. "The treatment of respiratory disease remains a high unmet need, despite the recent development of new therapies," David Hipkiss said in a statement. "The effective production and delivery of combination medicines in a consistent, stable and co-localised manner are lacking, given inefficiencies in current manufacturing and formulation processes."

The U.K. company recently completed a $27 million funding round, money it said it will use to develop its product pipeline, including a scaling-up of its multi-component particle platform.

- read Prosonix's release
- get in-PharmaTechnologist's take
- check out the company's release on its funding round